Trial · NCT06710990
Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
NCT06710990, Phase 1, Completed, Jiangsu HengRui Medicine Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer. Trials, record NCT06710990. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06710990
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
- NCT number
- NCT06710990
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 17 participants, actual
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Conditions
- Advanced Breast Cancer
- Interventions
- SHR-A1811, Ritonavir, Itraconazole
- First posted
- 2024-12-02
- Last updated
- 2026-06-04
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The maximum concentration (Cmax) for SHR-A1811 | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Primary | The maximum concentration (Cmax) for payload | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Primary | Area under the concentration curve from time 0 to 16 days (AUC0-16d) for SHR-A1811 | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Primary | Area under the concentration curve from time 0 to 16 days (AUC0-16d) for payload | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Secondary | Time to maximum plasma concentration (Tmax) | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Secondary | Terminal half-life (t1/2) | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Secondary | Area under the concentration curve from time 0 to infinity (AUCinf) | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Secondary | Clearance (CL) | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Secondary | Volume of distribution at steady state (Vss) | Cycle 2 and Cycle 3. Each cycle is 21 days. | |
| Secondary | Incidence and severity of adverse events | From the beginning of screening period to approximately 3 months after the last dose. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06710990
GET https://conductscience.org/api/trials/v1/NCT06710990/registered